A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).-MedSci.cn

A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Vaishampayan, UN; Keessen, M; Heath, EI; Dreicer, R; Buchler, T; Arkosy, PF; Csoszi, T; Wiechno, PJ; Kholtobin, D; Kopyltsov, E; Shore, ND; Nosov, A; Orlov, S; Plekhanov, A; Smagina, M; Varlamov, S; Vogelzang, NJ

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务